RGLS 21.43 Regulus Therapeutics Inc $RGLS Hit a 52
Post# of 46498
Posted On: 11/11/2014 2:28:39 PM
RGLS 21.43 Regulus Therapeutics Inc $RGLS Hit a 52 week high of 21.56 Currently at 21.43 +0.52 +2.49% With a day low of 20.51 and a total volume of 114,155.
RGLS Regulus Therapeutics Inc Recent Headline News
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), ACHN: 12.45 (-0.40), CNAT: 7.08 (+0.02), MRK: 59.38 (+0.57), RGLS: 19.98 (-0.93), ABBV: 63.56 (-0.23), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), ACHN: 12.45 (-0.40), CNAT: 7.08 (+0.02), MRK: 59.38 (+0.57), RGLS: 19.98 (-0.93), ABBV: 63.56 (-0.23), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), ACHN: 12.45 (-0.40), CNAT: 7.08 (+0.02), MRK: 59.38 (+0.57), LGND: 57.27 (+1.59), RGLS: 19.98 (-0.93), ABBV: 63.56 (-0.23), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), ACHN: 12.45 (-0.40), CNAT: 7.08 (+0.02), LGND: 57.27 (+1.59), RGLS: 19.98 (-0.93), ABBV: 63.56 (-0.23), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
Regulus Slumps: RGLS Falls 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:53AM CST
Regulus has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past 24 hours
ACRX: 6.88 (+0.85), AUXL: 32.47 (-0.23), ADHD: 3.66 (-0.01), RGLS: 19.98 (-0.93)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 108.24 (+1.22), ACHN: 12.45 (-0.40), RGLS: 19.98 (-0.93), ABBV: 63.55 (-0.24)
Regulus Therapeutics (RGLS) Strong On High Relative Volume Today
at The Street - Mon Nov 10, 9:04AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a strong on high relative volume candidate
RGLS: 19.98 (-0.93)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), CNAT: 7.08 (+0.02), MRK: 59.38 (+0.57), LGND: 57.27 (+1.59), RGLS: 19.98 (-0.93), ABBV: 63.56 (-0.23), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), CNAT: 7.08 (+0.02), MRK: 59.38 (+0.57), LGND: 57.27 (+1.59), RGLS: 19.98 (-0.93), ABBV: 63.55 (-0.24), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), CNAT: 7.08 (+0.02), MRK: 59.38 (+0.57), LGND: 57.27 (+1.59), RGLS: 19.98 (-0.93), ABBV: 63.56 (-0.23), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), ACHN: 12.45 (-0.40), CNAT: 7.08 (+0.02), MRK: 59.38 (+0.57), LGND: 57.27 (+1.59), RGLS: 19.98 (-0.93), ABBV: 63.56 (-0.23), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 324.02 (-3.85), ALNY: 99.10 (-0.08), ISIS: 51.04 (+3.81), OGXI: 2.15 (+0.02), TEVA: 58.18 (+0.14), RGLS: 19.98 (-0.93), GSK: 45.82 (+0.66), SNY: 47.08 (+0.89)
Regulus to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 10:30 a.m. MST. The conference is being held at the Arizona Biltmore in Phoenix, AZ.
RGLS: 19.98 (-0.93)
Insider Trading Alert - CBG, RGLS And WAB Traded By Insiders
at The Street - Thu Nov 06, 10:45AM CST
Stocks with insider trader activity include CBG, RGLS and WAB
CBG: 32.42 (+0.61), RGLS: 19.98 (-0.93), WAB: 89.53 (unch)
Regulus Therapeutics (RGLS) is in Overbought Territory: What's Next?
RGLS Regulus Therapeutics Inc Recent Headline News
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), ACHN: 12.45 (-0.40), CNAT: 7.08 (+0.02), MRK: 59.38 (+0.57), RGLS: 19.98 (-0.93), ABBV: 63.56 (-0.23), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), ACHN: 12.45 (-0.40), CNAT: 7.08 (+0.02), MRK: 59.38 (+0.57), RGLS: 19.98 (-0.93), ABBV: 63.56 (-0.23), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), ACHN: 12.45 (-0.40), CNAT: 7.08 (+0.02), MRK: 59.38 (+0.57), LGND: 57.27 (+1.59), RGLS: 19.98 (-0.93), ABBV: 63.56 (-0.23), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), ACHN: 12.45 (-0.40), CNAT: 7.08 (+0.02), LGND: 57.27 (+1.59), RGLS: 19.98 (-0.93), ABBV: 63.56 (-0.23), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
Regulus Slumps: RGLS Falls 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:53AM CST
Regulus has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past 24 hours
ACRX: 6.88 (+0.85), AUXL: 32.47 (-0.23), ADHD: 3.66 (-0.01), RGLS: 19.98 (-0.93)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 108.24 (+1.22), ACHN: 12.45 (-0.40), RGLS: 19.98 (-0.93), ABBV: 63.55 (-0.24)
Regulus Therapeutics (RGLS) Strong On High Relative Volume Today
at The Street - Mon Nov 10, 9:04AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a strong on high relative volume candidate
RGLS: 19.98 (-0.93)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), CNAT: 7.08 (+0.02), MRK: 59.38 (+0.57), LGND: 57.27 (+1.59), RGLS: 19.98 (-0.93), ABBV: 63.56 (-0.23), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), CNAT: 7.08 (+0.02), MRK: 59.38 (+0.57), LGND: 57.27 (+1.59), RGLS: 19.98 (-0.93), ABBV: 63.55 (-0.24), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), CNAT: 7.08 (+0.02), MRK: 59.38 (+0.57), LGND: 57.27 (+1.59), RGLS: 19.98 (-0.93), ABBV: 63.56 (-0.23), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.84 (+0.02), GILD: 108.24 (+1.22), ACHN: 12.45 (-0.40), CNAT: 7.08 (+0.02), MRK: 59.38 (+0.57), LGND: 57.27 (+1.59), RGLS: 19.98 (-0.93), ABBV: 63.56 (-0.23), BMY: 58.62 (-0.19), ENTA: 43.22 (-0.92)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 324.02 (-3.85), ALNY: 99.10 (-0.08), ISIS: 51.04 (+3.81), OGXI: 2.15 (+0.02), TEVA: 58.18 (+0.14), RGLS: 19.98 (-0.93), GSK: 45.82 (+0.66), SNY: 47.08 (+0.89)
Regulus to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 10:30 a.m. MST. The conference is being held at the Arizona Biltmore in Phoenix, AZ.
RGLS: 19.98 (-0.93)
Insider Trading Alert - CBG, RGLS And WAB Traded By Insiders
at The Street - Thu Nov 06, 10:45AM CST
Stocks with insider trader activity include CBG, RGLS and WAB
CBG: 32.42 (+0.61), RGLS: 19.98 (-0.93), WAB: 89.53 (unch)
Regulus Therapeutics (RGLS) is in Overbought Territory: What's Next?
(0)
(0)Scroll down for more posts ▼